Atlas Trials

A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas

Clinical trial NCT03575351 · COMPLETED

Trial details

NCT number
NCT03575351
Sponsor
Celgene
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Lymphoma, Non-Hodgkin
Start date
2018-10-23
Primary completion
2023-10-23
Enrollment
184

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.